Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolized Moli1901 in Adolescents and Adults with Cystic Fibrosis
2005-005594-29Phase 2Terminated
- Sponsor
- AOP Health
- Start
- Jun 2006
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing Moli1901 aerosol with Placebo aerosol (2 arms). Primary endpoint: Improvement in exercise capacity. Started Jun 2006; status: terminated.
02
Drugs
Lancovutide
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2005-005594-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005594-29.